Background Tauopathies are a class of neurodegenerative disorders characterized by
neuronal and/or glial tau-positive inclusions. Main body Clinically, tauopathies can present …

Recent drug development efforts targeting Alzheimer's disease (AD) have failed to produce
effective disease-modifying agents for many reasons, including the substantial …

Cytoplasmic aggregation and concomitant nuclear clearance of the RNA-binding protein
TDP-43 are found in~ 90% of cases of amyotrophic lateral sclerosis and~ 45% of patients …

Pathological forms of Tau protein are directly associated with neurodegeneration and
correlate with Alzheimer's Disease (AD) symptoms, progression, and severity. Previously …

Accumulation of misfolded proteins such as amyloid-β (Aβ), tau, and α-synuclein (α-Syn) in
the brain leads to synaptic dysfunction, neuronal damage, and the onset of relevant …

The development of peptide-based vaccines for treating human neurodegenerative
diseases has been the eventual aim of many research endeavors, although no active …

Background Alzheimer's disease (AD) is the most common cause of dementia in older adults
and characterized by progressive loss of memory and cognitive functions that are associated …

Tubulin-associated unit (tau) has been associated with more than 25 neurological disorders–
the so-called tauopathies. Hence, finding a novel therapeutic agent targeting tau to halt the …

Tauopathies are a group of neurological disorders, including Alzheimer's disease and
frontotemporal dementia, which involve progressive neurodegeneration, cognitive deficits …

Chronic traumatic encephalopathy (CTE) is a unique progressive neurodegenerative
tauopathy pathologically related to the aggregation of the tau protein to neurofibrillary …